Keyphrases
Adenosine Triphosphate
100%
Advanced Gastric Cancer
100%
Advanced or Metastatic
20%
Analytic Method
20%
Chemoresistant
20%
Chemosensitive
20%
Chemosensitivity
20%
Chemotherapy Response Assay
100%
Cisplatin
20%
Cisplatin-based Chemotherapy
100%
Clinical Response
40%
Combination Chemotherapy
20%
Confidence Interval
40%
Gastric Cancer Patients
20%
High Response Rate
20%
In Vitro Chemosensitivity
20%
Indexing Methods
20%
Individualized Tumor Response Testing
100%
Locally Advanced Gastric Cancer
20%
Median Overall Survival
20%
Median Progression-free Survival
20%
Metastatic Gastric Cancer
20%
Nave
20%
Negative Predictive Value
20%
Paclitaxel
20%
Paclitaxel Chemotherapy
100%
Patient Response
20%
Positive Predictive Value
20%
Prospective Clinical Trial
20%
Receiver Operating Characteristic Analysis
20%
Response Prediction
100%
ROC Analysis
20%
Study Support
20%
Validation Studies
20%
WHO Criteria
20%
Medicine and Dentistry
Abdominal Cancer
100%
Adenosine Triphosphate
71%
Chemosensitivity
28%
Chemotherapy
100%
Cisplatin
100%
Clinical Trial
14%
Combination Chemotherapy
14%
In Vitro
28%
Neoplasm
100%
Overall Survival
14%
Paclitaxel
100%
Progression Free Survival
14%
Pharmacology, Toxicology and Pharmaceutical Science
Abdominal Cancer
100%
Adenosine Triphosphate
62%
Chemotherapy
100%
Cisplatin
100%
Clinical Trial
12%
Neoplasm
100%
Overall Survival
12%
Paclitaxel
100%
Progression Free Survival
12%
Neuroscience
Adenosine Triphosphate
100%
Cisplatin
100%
In Vitro
40%
Paclitaxel
100%
Biochemistry, Genetics and Molecular Biology
Adenosine Triphosphate
100%
Chemosensitivity
40%
Cisplatin
100%
Clinical Trial
20%
Overall Survival
20%
Progression Free Survival
20%
Nursing and Health Professions